BRCC3 Antibodies

Lys-63-specific deubiquitinase BRCC36 (BRCC3)

Does not have action toward'Lys-48'-linked polyubiquitin chains. Component of the BRCA1-A complex, a complex that specifically recognizes'Lys-63'-connected ubiquitinated histones H2A and H2AX in DNA lesions sites, leading to target the BRCA1-BARD1 heterodimer to sites of DNA damage at double-strand breaks (DSBs).

In the BRCA1-A complex, it specifically removes'Lys-63'-linked ubiquitin on histones H2A and H2AX, antagonizing the RNF8-dependent ubiquitination at double- strand breaks (DSBs) (PubMed:20656690). Catalytic subunit of the BRISC complex, a multiprotein complex that specifically cleaves'Lys-63'-linked ubiquitin in a variety of substrates (PubMed:20656690, PubMed:24075985, PubMed:26344097, PubMed:26195665).

Gene Information

Human
Gene Name:	BRCC3
Uniprot:	P46736
Entrez:	79184

Family

Belongs to:
peptidase M67A family

Alternative Names

BRCA1/BRCA2-containing complex subunit 3; BRCA1/BRCA2-containing complex subunit 36; BRCA1/BRCA2-containing complex, subunit 3; BRCA1-A complex subunit BRCC36; BRCC36C6.1ACXorf53; BRISC complex subunit BRCC36; c6.1A; chromosome X open reading frame 53; EC 3.1.2.15; EC 3.4.19.-; lys-63-specific deubiquitinase BRCC36

Molecular Weight

Mass (kDA):
36.072 kDA

Genomic Context

Human
Location:	Xq28
Sequence:	X; NC_000023.11 (155071403..155126766)

Tissue Specificity

Heart, brain, placenta, lung, liver, skeletal muscle, kidney and pancreas. Aberrantly expressed in the vast majority of breast tumors.

Subcellular Localizations

Nucleus. Cytoplasm. Cytoplasm, cytoskeleton, spindle pole. Localizes at sites of DNA damage at double-strand breaks (DSBs) (PubMed:20656690, PubMed:26344097). Interaction with ABRAXAS2 retains BRCC3 in the cytoplasm (PubMed:20656690).

Diseases

• Malignant Neoplasms
• Neoplasms
• Malignant Neoplasm Of Breast
• Mammary Neoplasms
• Ovarian Neoplasm
• Malignant Neoplasm Of Ovary
• Aneurysm
• Coronary Heart Disease
• Embryonal Carcinoma
• Down Syndrome
• Neoplasms, Germ Cell And Embryonal
• Carcinoma

• Congenital Anomaly Of Face
• Tumor Angiogenesis
• Cytomegalovirus Infections
• Dwarfism
• Primary Hypogonadism
• Uterine Fibroids
• Pregnancy In Diabetics

Interacting Proteins

• ABRAXAS1

Pathways

• Dna Repair
• Cell Cycle
• Localization
• Methylation
• Dna Methylation
• Cell Proliferation
• Cell Death
• Dna Hypomethylation

• Hypersensitivity
• Angiogenesis
• Pathogenesis

PTMs

• Cleavage
• Methylation

• Phosphorylation
• Ubiquitination

For details, visit:
bosterbio.com/bosterbio-gene-info-cards/BRCC3

Best Uses of the BRCC3 Marker

As a scientist, you've probably heard about the BRCC3 marker and its benefits, but what is it and how do you use it? Depending on your research, it can help you make informed decisions regarding your species, research, or applications. In this article, we'll discuss the BRCC3 marker's uses and benefits and give you some optimization tips to make the most of this tool.

BRCC3 Marker

BRCC3 is a gene on the human genome that is responsible for the production of proteins in the body. The BRCC3 gene is involved in many processes in the body, including the production of insulin. The gene is important for the production of the protein insulin, which helps in the regulation of blood sugar levels. Currently, the BRCC3 gene is being investigated for its possible applications in the treatment of diabetes, cancer, and Alzheimer's disease.

Optima XE

BRCC3 is a tumor-associated gene that is often associated with myeloproliferative neoplasms and myelodysplastic syndromes. As such, it is an excellent candidate gene for predicting risk for a variety of myelodysplastic syndromes. The BRCC3 mutation can also be an indicator of MDS or MPN. Despite its potential importance for identifying patients with these disorders, there is no clear evidence that it will prevent or slow the progression of these diseases.

BRCC3 is a cancer-associated gene that regulates cellular cycle progression. Optima XE, a cell cycle marker, is a highly sensitive and accurate tool for the diagnosis of multiple types of tumors. Its detection has many clinical benefits. Optima XE is an effective tool for detecting tumors that have undergone surgery and have failed to respond to standard treatments.

The BRCC3 gene is responsible for determining cell radioresistance. This gene has a possible role in breast cancer. Moreover, a similar role is played by BRCC3 in patients with NPC, which accounts for the poor prognosis of patients with this disease. Thus, the role of BRCC3 in breast cancer research may be of great clinical value.

A recent study showed that BRCC3 expression was negatively associated with survival in NPC patients. The gene is associated with radioresistant NPC cells, and overexpression of BRCC3 was found in induced and inherent NPC cell lines. Knockdown of BRCC3 expression in HNE1 cells increased radiation sensitivity, inhibited DNA repair, and induced G2/M cell cycle arrest.

In the present study, the BRCC3 knockdown cells exhibited decreased levels of ionizing radiation after treatment. Moreover, their percentages of G2/M cells was significantly higher than those of control cells. Therefore, BRCC3 knockdown enhanced cell-cycle arrest in irradiated NPC cells. It may also increase radiation sensitivity in tumors. There are currently no approved cancer treatments that target the BRCC3 gene.

BRCC3 overexpression was associated with poorer survival in breast cancer patients and is linked to a higher risk of disease progression. This gene also confers increased radiation resistance to NPC cells. Inhibiting BRCC3 expression may be a promising therapeutic strategy to sensitize resistant NPC cells to radiation. There are many studies that support the effectiveness of this test. If you are interested in using it to detect breast cancer, check out the BRCC3 gene expression levels on your own cells.